IMCR

Business Context and Reporting Period

Immunocore Holdings Plc, a commercial-stage biotechnology company, filed its Form 10-Q for the quarterly period ended September 30, 2025. The company focuses on developing immunomodulating medicines using its proprietary ImmTAX platform. Its lead product, KIMMTRAK (tebentafusp), is approved in 39 countries for the treatment of unresectable or metastatic uveal melanoma and has been commercially launched in 28 countries.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 29.2% year-over-year for the quarter and 30.8% for the nine-month period, driven by increased sales volume in the United States and Europe and global expansion.
• Regional Performance: European revenue surged 58.9% in the quarter and 79.2% for the nine months, while U.S. revenue grew 17.5% and 15.4% respectively.
• Expense Increases: R&D expenses rose 33.7% for the quarter and 21.5% for the nine months, primarily due to increased external costs for PRAME programs (brenetafusp), tebentafusp Phase 3 trials, and autoimmune program development.
• Profitability: The company reported a net loss of $0.2 million for the quarter compared to a net income of $8.7 million in the prior year quarter. For the nine months, the net loss was $5.5 million compared to $27.3 million in the prior year, representing a significant improvement in the loss position.
• Interest Income: Interest income decreased due to lower interest rates on money market funds and reduced cash balances following the purchase of marketable securities.

Guidance, Outlook, and Risks

• Clinical Updates: The Independent Data Monitoring Committee recommended 160 mcg as the go-forward dose for brenetafusp in the PRISM-MEL-301 Phase 3 trial for advanced cutaneous melanoma.
• Liquidity: Management expects existing cash, marketable securities, and anticipated revenue to fund operations for at least twelve months from the filing date. However, the company anticipates continued operating losses and may seek additional financing for long-term clinical development.
• Manufacturing: A global recall was initiated in June 2025 for one batch of KIMMTRAK due to stability testing results; management does not expect a material financial impact.
• Key Risks:
  • Tariffs and Trade: New U.S.-EU tariff agreements may increase the cost of importing products manufactured in the EU, potentially reducing margins.
  • Geopolitical Instability: Conflicts in Ukraine and the Middle East pose risks to supply chains, clinical trial execution, and commercialization in affected regions.
  • Reimbursement: Revenue recognition relies on estimates for rebates and chargebacks, particularly in European markets where pricing negotiations are ongoing.

Investor Verification Checklist

• Verify the impact of the June 2025 KIMMTRAK batch recall on future production schedules and costs.
• Monitor the progress of the PRISM-MEL-301 Phase 3 trial for brenetafusp following the dose selection recommendation.
• Assess the potential financial impact of new U.S. tariffs on EU-manufactured pharmaceuticals on future gross margins.
• Review the company's cash burn rate relative to its $892.3 million total liquid assets (cash + marketable securities) to confirm the 12-month runway.
• Track the resolution of pricing negotiations in France and other European markets to validate revenue accrual estimates.